BACKGROUND: Intimal hyperplasia (IH), a cause of early graft failure, may be regulated by leukocyte-elaborated cytokines. We investigated leukocyte infiltration and cytokine gene expression in vein grafts. METHODS: Epigastric vein to femoral artery grafts were performed in Lewis rats and harvested on day 4 and weeks 1, 2, 4, 8, and 12. Neointimal areas were measured by computerized planimetry. Immunoperoxidase staining identified for macrophages, CD4+, CD8+, and major histocompatibility complex class II+ cells. Graft RNA was used in reversetranscription-polymerase chain reaction with interleukin (IL)-1 alpha, IL-2R, monocyte chemoattractant protein-1, and transforming growth factor-beta primers. RESULTS: IH was measurable at 2 weeks; the perianastomotic regions displayed greater IH than the midgraft (p < 0.05). MANOVA indicated strong location (p = 0.0001) and time (p = 0.0009) effects. Immunocytochemistry showed inflammatory infiltrates from 4 days to 4 major histocompatibility complex class II+ and primarily monocyte/macrophages, with less frequent T lymphocytes (CD4+ > CD8+). IL-1 alpha messenger RNA is expressed early, disappearing after 4 weeks. Monocyte chemoattracta t protein-1 mRNA is constitutively expressed, with up-regulation at 4 days to 4 weeks. IL-2R mRNA levels fluctuate; transforming growth factor-beta is always expressed, peaking at 4 days to 4 weeks. CONCLUSIONS: Gene expression of cytokines thought to modulate IH is up-regulated early in vein grafts. This coincides with graft infiltration by activated leukocytes before and during the development of IH.
BACKGROUND: Intimal hyperplasia (IH), a cause of early graft failure, may be regulated by leukocyte-elaborated cytokines. We investigated leukocyte infiltration and cytokine gene expression in vein grafts. METHODS: Epigastric vein to femoral artery grafts were performed in Lewis rats and harvested on day 4 and weeks 1, 2, 4, 8, and 12. Neointimal areas were measured by computerized planimetry. Immunoperoxidase staining identified for macrophages, CD4+, CD8+, and major histocompatibility complex class II+ cells. Graft RNA was used in reversetranscription-polymerase chain reaction with interleukin (IL)-1 alpha, IL-2R, monocyte chemoattractant protein-1, and transforming growth factor-beta primers. RESULTS: IH was measurable at 2 weeks; the perianastomotic regions displayed greater IH than the midgraft (p < 0.05). MANOVA indicated strong location (p = 0.0001) and time (p = 0.0009) effects. Immunocytochemistry showed inflammatory infiltrates from 4 days to 4 major histocompatibility complex class II+ and primarily monocyte/macrophages, with less frequent T lymphocytes (CD4+ > CD8+). IL-1 alpha messenger RNA is expressed early, disappearing after 4 weeks. Monocyte chemoattracta t protein-1 mRNA is constitutively expressed, with up-regulation at 4 days to 4 weeks. IL-2R mRNA levels fluctuate; transforming growth factor-beta is always expressed, peaking at 4 days to 4 weeks. CONCLUSIONS: Gene expression of cytokines thought to modulate IH is up-regulated early in vein grafts. This coincides with graft infiltration by activated leukocytes before and during the development of IH.
Authors: Atsunori Nakao; Chien-Sheng Huang; Donna B Stolz; Yinna Wang; Jonathan M Franks; Naobumi Tochigi; Timothy R Billiar; Yoshiya Toyoda; Edith Tzeng; Kenneth R McCurry Journal: Cardiovasc Res Date: 2010-09-16 Impact factor: 10.787
Authors: Christopher D Owens; Paul M Ridker; Michael Belkin; Allen D Hamdan; Frank Pomposelli; Frank Logerfo; Mark A Creager; Michael S Conte Journal: J Vasc Surg Date: 2006-11-21 Impact factor: 4.268
Authors: Thomas A Abbruzzese; Joaquim Havens; Michael Belkin; Magruder C Donaldson; Anthony D Whittemore; James K Liao; Michael S Conte Journal: J Vasc Surg Date: 2004-06 Impact factor: 4.268
Authors: Karl A Nath; Sharan K R Kanakiriya; Joseph P Grande; Anthony J Croatt; Zvonimir S Katusic Journal: Am J Pathol Date: 2003-06 Impact factor: 4.307
Authors: Geoffrey T L Kloppenburg; Rick de Graaf; Gert E L M Grauls; Cathrien A Bruggeman; Frank R Stassen Journal: BMC Microbiol Date: 2007-12-06 Impact factor: 3.605